The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 10 World Allergy Organization (WAO). 11 Busse WW.

Trials 52

Trials Production Sales Manufacturing 52

XTalks

NOVEMBER 30, 2023

More Investigational Therapies for HIV Are on the Way American Gene Technologies, a pioneering biotech company headquartered in Rockville, Maryland, has released promising results from its Phase I trial of AGT103-T, a gene therapy designed for individuals with chronic HIV disease. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

JULY 8, 2021

Specifically, tezepelumab targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.(24,25). EMJ Allergy Immunol.

Allergies 52

Allergies Trials In-Vivo Medicine 52

Scienmag

OCTOBER 9, 2020

Findings could lay the foundation for the development of effective therapeutic and malaria vaccine strategies, which has largely been hindered by a lack of understanding of the host immune response Credit: Aissatou Diawara Abu Dhabi, UAE, October 9, 2020: The Plasmodium parasite, which transmits malaria to humans through infected mosquitos, triggers (..)

Immune Response 52

Immune Response Gene Research Vaccination 52

Delveinsight

JANUARY 21, 2021

The gene TP53 produces the protein p53, a known tumour suppressor. TP53 is frequently mutated across various cancers, so targeting the gene is a popular pursuit in oncology research. The new research provides a scientific rationale to advance clinical studies of the drug combination in patients with AML. Jacob Van Naarden, M.D.,

Research 52

Research Protein Clinical Trials Clinical Trials 52

The Pharma Data

APRIL 27, 2021

to €283 million, reflecting growth of Digestive and Mental Wellness categories as well as Allergy partially offset by the decline of the Pain category. Development for Dupixent ® for grass allergy has been discontinued. At CER, BOI increased 48.6%. The ratio of BOI to net sales was 40.5% (and 27.5% Consumer Healthcare. Change at CER.

Sales 52

Sales Vaccination Vaccine Medicine 52

XTalks

MAY 2, 2024

Some treatments already on the market have grabbed additional approvals in 2024, including Novo Nordisk’s Wegovy (semaglutide) for cardiovascular risk reduction, Dupixent (dupilumab) for eosinophilic esophagitis (EoE) in young children and Xolair (omalizumab) for food allergies.

Drugs 52

Drugs FDA Approval Vaccination Vaccine 52

pharmaphorum

JULY 26, 2022

The hope of being able to provide a functional or complete cure for AIDS is being raised by the prospect of utilising recent developments in the industry, including gene therapy and mRNA vaccines. Gene therapies are another approach that has been validated with approvals in recent years.

Gene Therapy 140

Gene Therapy Protein Vaccination Vaccine 140

XTalks

SEPTEMBER 14, 2020

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. China’s COVID-19 Vaccine: Sinovac Biotech and CanSino Biologics.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92